Calculate the Padua VTE risk score for medical inpatients. Identifies hospitalized patients who benefit from thromboprophylaxis based on 11 risk factors.
The Padua Prediction Score is the most widely validated risk assessment model for venous thromboembolism (VTE) in medical inpatients. Published by Barbar et al. in 2010, it uses 11 clinical risk factors to identify hospitalized medical patients at high risk for DVT and PE who would benefit from pharmacologic thromboprophylaxis.
Hospital-associated VTE accounts for approximately 60% of all VTE events and is the leading preventable cause of hospital death. Despite clear evidence that anticoagulant prophylaxis reduces VTE by 40-60%, studies consistently show under-prophylaxis rates of 30-50% among medical inpatients. Systematic risk assessment using the Padua score targets prophylaxis to high-risk patients while avoiding unnecessary anticoagulation in low-risk patients.
A Padua score ≥4 identifies patients with approximately 11% VTE risk over 30 days without prophylaxis, compared to <1% in low-risk patients (score <4). This threshold guides the decision to initiate pharmacologic prophylaxis with low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH). Check the example with realistic values before reporting.
Pharmacologic VTE prophylaxis is not risk-free — it increases bleeding complications. The Padua score enables targeted prophylaxis: patients scoring ≥4 have a favorable benefit-to-risk ratio for anticoagulant prophylaxis, while those <4 are better served by non-pharmacologic measures alone (early ambulation, hydration, mechanical prophylaxis if immobile).
The ACCP (American College of Chest Physicians) guidelines recommend against universal pharmacologic prophylaxis for all medical inpatients, endorsing risk-stratified approaches using validated tools like the Padua score.
Padua Score = Sum of: Active cancer: 3 pts Previous VTE: 3 pts Reduced mobility (≥3 days): 3 pts Known thrombophilia: 3 pts Recent trauma/surgery (≤1 month): 2 pts Age ≥70: 1 pt Heart/respiratory failure: 1 pt Acute MI or ischemic stroke: 1 pt Acute infection/rheumatic disorder: 1 pt Obesity (BMI ≥30): 1 pt Ongoing hormonal treatment: 1 pt Range: 0-20 <4: Low risk | ≥4: High risk → prophylaxis
Result: Padua Score 8 — High Risk
Active cancer (3) + reduced mobility (3) + age ≥70 (1) + obesity (1) = 8 points. This is well above the threshold of 4, indicating high VTE risk. Pharmacologic prophylaxis with enoxaparin 40mg SC daily should be initiated after confirming no major bleeding contraindications.
Pharmacologic options: Enoxaparin 40mg SC daily (most studied), Dalteparin 5000 IU SC daily, UFH 5000U SC q8h or q12h (for CrCl <30), Fondaparinux 2.5mg SC daily. Mechanical options: Graduated compression stockings (GCS), Intermittent pneumatic compression (IPC) devices. For high-risk patients, pharmacologic prophylaxis is superior to mechanical alone.
Critically ill patients: Higher VTE risk but also higher bleeding risk. LMWH is preferred over UFH when feasible. Obese patients (BMI >40): Consider higher-dose LMWH (enoxaparin 40mg SC q12h). Renal impairment: UFH preferred if CrCl <30; if LMWH used, monitor anti-Xa levels. Pregnancy: Padua not validated; use obstetric-specific scores (RCOG).
VTE prophylaxis is a Joint Commission core measure and CMS quality metric. Hospitals must demonstrate ≥85% compliance with appropriate prophylaxis for at-risk patients. Electronic clinical decision support with Padua scoring has been shown to improve prophylaxis rates from 50-60% to 85-95%.
No. The Padua score was developed and validated for MEDICAL inpatients. Surgical patients should use the Caprini score or Rogers score, which account for procedure-specific risk factors (type of surgery, duration, anesthesia type). Surgical VTE prophylaxis follows separate guidelines.
Use the IMPROVE bleeding risk score to assess bleeding risk. For patients with both high VTE risk (Padua ≥4) and high bleeding risk, mechanical prophylaxis (graduated compression stockings or intermittent pneumatic compression devices) is recommended over pharmacologic prophylaxis. Reassess daily — when bleeding risk decreases, switch to pharmacologic prophylaxis.
Standard duration: throughout the hospital stay and until the patient is fully mobile. Extended prophylaxis (up to 45 days) may benefit select higher-risk patients (the EXCLAIM and MARINER trials showed modest benefit in high-risk subgroups, but with increased bleeding). Extended-duration betrixaban was FDA-approved based on APEX trial data.
LMWH (enoxaparin 40mg SC daily) is generally preferred over UFH for better bioavailability, once-daily dosing, and lower HIT risk. UFH 5000U SC q8-12h is an alternative for renal impairment (CrCl <30). DOACs are not routinely recommended for medical inpatient prophylaxis (MAGELLAN and MARINER had mixed results).
Bed rest with bathroom privileges for an anticipated ≥3 days. This includes patients who are too ill to ambulate, those on strict bed rest for medical reasons, and patients with conditions that severely limit mobility (e.g., paralysis, severe pain). Brief periods out of bed for toileting alone still qualify.
For medical inpatients, aspirin is NOT considered adequate VTE prophylaxis. While low-dose aspirin has shown some benefit in post-surgical VTE prevention (EPCAT II, CRISTAL trials), it is significantly less effective than LMWH for medical thromboprophylaxis. Patients on aspirin for cardiac indications who are Padua ≥4 should receive LMWH prophylaxis.